Application of reproductive hormone peptides for tumor targeting

Current Pharmaceutical Biotechnology

Volumn 12, Issue 8, 2011, Pages 1144-1152

  Zhang, Xiaoyan ^a   Xu, Congjian ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Cancer treatment; Drug delivery system; Hormone peptide; Receptor; Reproductive hormone; Tumor targeting

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BRCA1 PROTEIN; CAMPTOTHECIN; CARBOPLATIN; CHOLECYSTOKININ DERIVATIVE; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN RECEPTOR; DESLORELIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLLITROPIN; GONADORELIN; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] 2 PYRROLINODOXORUBICIN; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; HEAT SHOCK PROTEIN 65; LUTEINIZING HORMONE; MYC PROTEIN; NANOCARRIER; PACLITAXEL; PEPTIDE HORMONE; PROTEIN BCL 2; PROTEIN C FOS; PROTEIN C JUN; RADIOPHARMACEUTICAL AGENT; SMALL INTERFERING RNA; SOMATOSTATIN DERIVATIVE; VASCULOTROPIN;

ADRENAL CORTEX TUMOR; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BLOOD TOXICITY; CANCER CELL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; ENDOCYTOSIS; ENDOMETRIUM CANCER; GENE EXPRESSION; GRANULOSA CELL TUMOR; HUMAN; INTERNALIZATION; LEYDIG CELL TUMOR; MOLECULARLY TARGETED THERAPY; OVARY CANCER; OVULATION; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CHORIONIC GONADOTROPIN; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEINIZING HORMONE; NEOPLASMS; PEPTIDE HORMONES; RECEPTORS, FSH; RECEPTORS, LH; RECEPTORS, LHRH; RECEPTORS, NEUROPEPTIDE;

EID: 79960026129     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111796117427     Document Type: Review

References (120)

1. Schally, A. V.; Nagy, A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol. Metab., 2004, 15, 300-310.
2. Magrath, I. T. Targeted approaches to cancer therapy. Int. J. Cancer, 1994, 56, 163-166.
3. Oyen, W. J.; Bodei, L.; Giammarile, F.; Maecke, H. R.; Tennvall, J.; Luster, M.; Brans, B. Targeted therapy in nuclear medicine-current status and future prospects. Ann. Oncol., 2007, 18, 1782-1792.
4. Reubi, J. C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev., 2003, 24, 389-427.
5. Kumar, P.; Wu, H.; McBride, J. L.; Jung, K. E.; Kim, M. H.; Davidson, B. L.; Lee, S. K.; Shankar, P.; Manjunath, N. Transvascular delivery of small interfering RNA to the central nervous system. Nature, 2007, 448, 39-43.
6. Schally, A. V.; Nagy, A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol., 1999, 141, 1-14.
7. Cai, H.; Yang, H.; Xiang, B.; Li, S.; Liu, S.; Wan, L.; Zhang, J.; Li, Y.; Cheng, J.; Lu, X. Selective apoptotic killing of solid and hematologic tumor cells by bombesin-targeted delivery of mitochondriadisrupting peptides. Mol. Pharm., 2010, 7, 586-596.
8. Chen, W.; Bardhan, R.; Bartels, M.; Perez-Torres, C.; Pautler, R. G.; Halas, N. J.; Joshi, A. A molecularly targeted theranostic probe for ovarian cancer. Mol. Cancer Ther., 2010, 9, 1028-1038.
9. Mabuchi, S.; Morishige, K.; Kimura, T. Use of monoclonal antibodies in the treatment of ovarian cancer. Curr. Opin. Obstet. Gynecol., 2010, 22, 3-8.
10. Frederick, P. J.; Straughn, J. J.; Alvarez, R. D.; Buchsbaum, D. J. Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol. Oncol., 2009, 113, 384-390.
11. Mezo, G.; Manea, M. Receptor-mediated tumor targeting based on peptide hormones. Expert Opin. Drug Deliv., 2010, 7, 79-96.
12. Schally, A. V.; Arimura, A.; Kastin, A. J.; Matsuo, H.; Baba, Y.; Redding, T. W.; Nair, R. M.; Debeljuk, L.; White, W. F. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science, 1971, 173, 1036-1038.
13. Parhar, I. S.; Ogawa, S.; Sakuma, Y. Three GnRH receptor types in laser-captured single cells of the cichlid pituitary display cellular and functional heterogeneity. Proc. Natl. Acad. Sci. U S A., 2005, 102, 2204-2209.
14. Huang, W.; Yao, B.; Sun, L.; Pu, R.; Wang, L.; Zhang, R. Immunohistochemical and in situ hybridization studies of gonadotropin releasing hormone (GnRH) and its receptor in rat digestive tract. Life Sci., 2001, 68, 1727-1734.
15. Casan, E. M.; Raga, F.; Bonilla-Musoles, F.; Polan, M. L. Human oviductal gonadotropin-releasing hormone: possible implications in fertilization, early embryonic development, and implantation. J. Clin. Endocrinol. Metab., 2000, 85, 1377-1381.
16. Chen, H. F.; Jeung, E. B.; Stephenson, M.; Leung, P. C. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J. Clin. Endocrinol. Metab., 1999, 84, 743-750.
17. Raga, F.; Casan, E. M.; Kruessel, J. S.; Wen, Y.; Huang, H. Y.; Nezhat, C.; Polan, M. L. Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle. Biol. Reprod., 1998, 59, 661-669.
18. Chegini, N.; Rong, H.; Dou, Q.; Kipersztok, S.; Williams, R. S. Gonadotropin-releasing hormone (GnRH) and GnRH receptor gene expression in human myometrium and leiomyomata and the direct action of GnRH analogs on myometrial smooth muscle cells and interaction with ovarian steroids in vitro. J. Clin. Endocrinol. Metab., 1996, 81, 3215-3221.
19. Ho, J. S.; Nagle, G. T.; Mathias, J. R.; Clench, M. H.; Fan, X.; Kalmaz, G. D.; Sallustio, J. E.; Eaker, E. Y. Presence of gonadotropin-releasing hormone (GnRH) receptor mRNA in rat myenteric plexus cells. Comp. Biochem. Physiol. B Biochem. Mol. Biol., 1996, 113, 817-821.
20. Grundker, C.; Gunthert, A. R.; Westphalen, S.; Emons, G. Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur. J. Endocrinol., 2002, 146, 1-14.
21. Yeung, C. M.; An, B. S.; Cheng, C. K.; Chow, B. K.; Leung, P. C. Expression and transcriptional regulation of the GnRH receptor gene in human neuronal cells. Mol. Hum. Reprod., 2005, 11, 837-842.
22. Keller, G.; Schally, A. V.; Gaiser, T.; Nagy, A.; Baker, B.; Westphal, G.; Halmos, G.; Engel, J. B. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue. Cancer Res., 2005, 65, 5857-5863.
23. Lamharzi, N.; Halmos, G.; Armatis, P.; Schally, A. V. Expression of mRNA for luteinizing hormone-releasing hormone receptors and epidermal growth factor receptors in human cancer cell lines. Int. J. Oncol., 1998, 12, 671-675.
24. Keller, G.; Schally, A. V.; Gaiser, T.; Nagy, A.; Baker, B.; Halmos, G.; Engel, J. B. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues. Clin. Cancer Res., 2005, 11, 5549-5557.
25. Keller, G.; Schally, A. V.; Gaiser, T.; Nagy, A.; Baker, B.; Halmos, G.; Engel, J. B. Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. Eur. J. Cancer, 2005, 41, 2196-2202.
26. Szepeshazi, K.; Schally, A. V.; Halmos, G. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy. Int. J. Oncol., 2007, 30, 1485-1492.
27. Emons, G.; Pahwa, G. S.; Brack, C.; Sturm, R.; Oberheuser, F.; Knuppen, R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur. J. Cancer Clin. Oncol., 1989, 25, 215-221.
28. Srkalovic, G.; Schally, A. V.; Wittliff, J. L.; Jr. Day, T. G.; Jenison, E. L. Presence and characteristics of receptors for [DTrp6] luteinizing hormone releasing hormone and epidermal growth factor in human ovarian cancer. Int. J. Oncol., 1998, 12, 489-498.
29. Volker, P.; Grundker, C.; Schmidt, O.; Schulz, K. D.; Emons, G. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am. J. Obstet. Gynecol., 2002, 186, 171-179.
30. Minegishi, T.; Nakamura, K.; Takakura, Y.; Miyamoto, K.; Hasegawa, Y.; Ibuki, Y.; Igarashi, M.; Minegish, T. Cloning and sequencing of human LH/hCG receptor cDNA. Biochem. Biophys. Res. Commun., 1990, 172, 1049-1054.
31. Minegishi, T.; Nakamura, K.; Takakura, Y.; Ibuki, Y.; Igarashi, M.; Minegish, T. Cloning and sequencing of human FSH receptor cDNA. Biochem. Biophys. Res. Commun., 1991, 175, 1125-1130.
32. Puett, D.; Li, Y.; DeMars, G.; Angelova, K.; Fanelli, F. A functional transmembrane complex: the luteinizing hormone receptor with bound ligand and G protein. Mol. Cell. Endocrinol., 2007, 260-262, 126-136.
33. Bose, C. K. Does hormone replacement therapy prevent epithelial ovarian cancer? Reprod. Biomed. Online, 2005, 11, 86-92.
34. Jr. Landen, C. N.; Birrer, M. J.; Sood, A. K. Early events in the pathogenesis of epithelial ovarian cancer. J. Clin. Oncol., 2008, 26, 995-1005.
35. Jernstrom, H.; Borg, K.; Olsson, H. High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk. Mol. Genet. Metab., 2005, 86, 320-327.
36. Konishi, I. Gonadotropins and ovarian carcinogenesis: a new era of basic research and its clinical implications. Int. J. Gynecol. Cancer, 2006, 16, 16-22.
37. Celik, C.; Gezginc, K.; Aktan, M.; Acar, A.; Yaman, S. T.; Gungor, S.; Akyurek, C. Effects of ovulation induction on ovarian morphology: an animal study. Int. J. Gynecol. Cancer, 2004, 14, 600-606.
38. Kammerman, S.; Demopoulos, R. I.; Raphael, C.; Ross, J. Gonadotropic hormone binding to human ovarian tumors. Hum. Pathol., 1981, 12, 886-890.
39. Nakano, R.; Kitayama, S.; Yamoto, M.; Shima, K.; Ooshima, A. Localization of gonadotropin binding sites in human ovarian neoplasms. Am. J. Obstet. Gynecol., 1989, 161, 905-910.
40. Al-Timimi, A.; Buckley, C. H.; Fox, H. An immunohistochemical study of the incidence and significance of human gonadotrophin and prolactin binding sites in normal and neoplastic human ovarian tissue. Br. J. Cancer, 1986, 53, 321-329.
41. Zheng, W.; Magid, M. S.; Kramer, E. E.; Chen, Y. T. Folliclestimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am. J. Pathol., 1996, 148, 47-53.
42. Parrott, J. A.; Doraiswamy, V.; Kim, G.; Mosher, R.; Skinner, M. K. Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol. Cell. Endocrinol., 2001, 172, 213-222.
43. Syed, V.; Ulinski, G.; Mok, S. C.; Yiu, G. K.; Ho, S. M. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res., 2001, 61, 6768-6776.
44. Minegishi, T.; Kameda, T.; Hirakawa, T.; Abe, K.; Tano, M.; Ibuki, Y. Expression of gonadotropin and activin receptor messenger ribonucleic acid in human ovarian epithelial neoplasms. Clin. Cancer Res., 2000, 6, 2764-2770.
45. Zheng, W.; Lu, J. J.; Luo, F.; Zheng, Y.; Feng, Y.; Felix, J. C.; Lauchlan, S. C.; Pike, M. C. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol. Oncol., 2000, 76, 80-88.
46. Wang, J.; Lin, L.; Parkash, V.; Schwartz, P. E.; Lauchlan, S. C.; Zheng, W. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. Int. J. Cancer, 2003, 103, 328-334.
47. Jankowska, A. G.; Andrusiewicz, M.; Fischer, N.; Warchol, P. J. Expression of hCG and GnRHs and their receptors in endometrial carcinoma and hyperplasia. Int. J. Gynecol. Cancer, 2010, 20, 92-101.
48. Jankowska, A.; Andrusiewicz, M.; Grabowski, J.; Nowak-Markwitz, E.; Warchol, J. B. Coexpression of human chorionic gonadotropin beta subunit and its receptor in nontrophoblastic gynecological cancer. Int. J. Gynecol. Cancer, 2008, 18, 1102-1107.
49. Nikula, H.; Koskimies, P.; El-Hefnawy, T.; Huhtaniemi, I. Functional characterization of the basal promoter of the murine LH receptor gene in immortalized mouse Leydig tumor cells. J. Mol. Endocrinol., 2001, 26, 21-29.
50. Ben-Josef, E.; Yang, S. Y.; Ji, T. H.; Bidart, J. M.; Garde, S. V.; Chopra, D. P.; Porter, A. T.; Tang, D. G. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J. Urol., 1999, 161, 970-976.
51. Viswanath, G.; Chatterjee, S.; Roy, P. Assessment of luteinizing hormone receptor function in an endometrial cancer cell line, Ishikawa cells in response to human chorionic gonadotrophin (hCG). Mol. Cell Endocrinol., 2007, 272, 14-21.
52. Hudelist, G.; Wuelfing, P.; Czerwenka, K.; Knofler, M.; Haider, S.; Fink-Retter, A.; Gschwantler-Kaulich, D.; Pfeiler, G.; Kubista, E.; Singer, C. F. Beta-hCG/LH receptor (b-HCG/LH-R) expression is increased in invasive versus preinvasive breast cancer: implications for breast carcinogenesis? J. Cancer Res. Clin. Oncol., 2009, 135, 191-195.
53. Jun, J. K.; Yoon, J. S.; Ku, S. Y.; Choi, Y. M.; Hwang, K. R.; Park, S. Y.; Lee, G. H.; Lee, W. D.; Kim, S. H.; Kim, J. G.; Moon, S. Y. Follicle-stimulating hormone receptor gene polymorphism and ovarian responses to controlled ovarian hyperstimulation for IVFET. J. Hum. Genet., 2006, 51, 665-670.
54. Yang, C. Q.; Chan, K. Y.; Ngan, H. Y.; Khoo, U. S.; Chiu, P. M.; Chan, Q. K.; Xue, W. C.; Cheung, A. N. Single nucleotide polymorphismsof follicle-stimulating hormone receptor are associatedwith ovarian cancer susceptibility. Carcinogenesis, 2006, 27, 1502-1506.
55. Ludwig, A. H.; Murawska, M.; Panek, G.; Timorek, A.; Kupryjanczyk, J. Androgen, progesterone, and FSH receptor polymorphismsin ovarian cancer risk and outcome. Endocr. Relat. Cancer,2009, 16, 1005-1016.
56. Wang, J.; Luo, F.; Lu, J. J.; Chen, P. K.; Liu, P.; Zheng, W. VEGFexpression and enhanced production by gonadotropins in ovarianepithelial tumors. Int. J. Cancer, 2002, 97, 163-167.
57. Choi, J. H.; Choi, K. C.; Auersperg, N.; Leung, P. C. Gonadotropinsupregulate the epidermal growth factor receptor through activationof mitogen-activated protein kinases and phosphatidylinositol-3-kinase in human ovarian surface epithelial cells. Endocr.Relat. Cancer, 2005, 12, 407-421.
58. Choi, J. H.; Choi, K. C.; Auersperg, N.; Leung, P. C. Overexpressionof follicle-stimulating hormone receptor activates oncogenicpathways in preneoplastic ovarian surface epithelial cells. J. Clin.Endocrinol. Metab., 2004, 89, 5508-5516.
59. Ji, Q.; Liu, P. I.; Chen, P. K.; Aoyama, C. Follicle stimulatinghormone-induced growth promotion and gene expression profileson ovarian surface epithelial cells. Int. J. Cancer, 2004, 112, 803-814.
60. Choi, J. H.; Choi, K. C.; Auersperg, N.; Leung, P. C. Differentialregulation of two forms of gonadotropin-releasing hormone messengerribonucleic acid by gonadotropins in human immortalizedovarian surface epithelium and ovarian cancer cells. Endocr. Relat.Cancer, 2006, 13, 641-651.
61. Mertens-Walker, I.; Bolitho, C.; Baxter, R. C.; Marsh, D. J. Gonadotropin-induced ovarian cancer cell migration and proliferationrequire extracellular signal-regulated kinase 1/2 activation regulatedby calcium and protein kinase C{delta}. Endocr. Relat. Cancer,2010, 17, 335-349.
62. Sapoznik, S.; Cohen, B.; Tzuman, Y.; Meir, G.; Ben-Dor, S.; Harmelin, A.; Neeman, M. Gonadotropin-regulated lymphangiogenesisin ovarian cancer is mediated by LEDGF-induced expression ofVEGF-C. Cancer Res., 2009, 69, 9306-9314.
63. Lau, M. T.; Wong, A. S.; Leung, P. C. Gonadotropins induce tumorcell migration and invasion by increasing cyclooxygenases expressionand prostaglandin E(2) production in human ovarian cancercells. Endocrinology, 2010, 151, 2985-2993.
64. Piersma, D.; Berns, E. M.; Verhoef-Post, M.; Uitterlinden, A. G.; Braakman, I.; Pols, H. A.; Themmen, A. P. A common polymorphismrenders the luteinizing hormone receptor protein more activeby improving signal peptide function and predicts adverse outcomein breast cancer patients. J. Clin. Endocrinol. Metab., 2006, 91,1470-1476.
65. Mazzuco, T. L.; Chabre, O.; Feige, J. J.; Thomas, M. Aberrantexpression of human luteinizing hormone receptor by adrenocorticalcells is sufficient to provoke both hyperplasia and Cushing'ssyndrome features. J. Clin. Endocrinol. Metab., 2006, 91, 196-203.
66. Vuorenoja, S.; Rivero-Muller, A.; Kiiveri, S.; Bielinska, M.; Heikinheimo, M.; Wilson, D. B.; Huhtaniemi, I. T.; Rahman, N.A. Adrenocortical tumorigenesis, luteinizing hormone receptor andtranscription factors GATA-4 and GATA-6. Mol. Cell Endocrinol.,2007, 269, 38-45.
67. Jankowska, A. G.; Andrusiewicz, M.; Fischer, N.; Warchol, P. J. Expression of hCG and GnRHs and their receptors in endometrialcarcinoma and hyperplasia. Int. J. Gynecol. Cancer, 2010, 20, 92-101.
68. Freimann, S.; Ben-Ami, I.; Hirsh, L.; Dantes, A.; Halperin, R.; Amsterdam, A. Drug development for ovarian hyper-stimulationand anti-cancer treatment: blocking of gonadotropin signaling forepiregulin and amphiregulin biosynthesis. Biochem. Pharmacol.,2004, 68, 989-996.
69. Wadia, P. R.; Mahale, S. D.; Nandedkar, T. D. Effect of the humanfollicle-stimulating hormone-binding inhibitor and its N-terminalfragment on follicle-stimulating hormone-induced progesterone secretionby granulosa cells in vitro. J. Biosci., 2007, 32, 1185-1194.
70. Bose, C. K. Follicle stimulating hormone receptor (FSHR) antagonistand epithelial ovarian cancer (EOC). J. Exp. Ther. Oncol.,2007, 6, 201-204.
71. Schally, A. V. New approaches to the therapy of various tumorsbased on peptide analogues. Horm. Metab. Res., 2008, 40, 315-322.
72. Nagy, A.; Schally, A. V.; Armatis, P.; Szepeshazi, K.; Halmos, G.; Kovacs, M.; Zarandi, M.; Groot, K.; Miyazaki, M.; Jungwirth, A.;Horvath, J. Cytotoxic analogs of luteinizing hormone-releasinghormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative500-1000 times more potent. Proc. Natl. Acad. Sci. U S A.,1996, 93, 7269-7273.
73. Westphalen, S.; Kotulla, G.; Kaiser, F.; Krauss, W.; Werning, G.; Elsasser, H. P.; Nagy, A.; Schulz, K. D.; Grundker, C.; Schally, A.V.; Emons, G. Receptor mediated antiproliferative effects of thecytotoxic LHRH agonist AN-152 in human ovarian and endometrialcancer cell lines. Int. J. Oncol., 2000, 17, 1063-1069.
74. Arencibia, J. M.; Schally, A. V.; Halmos, G.; Nagy, A.; Kiaris, H. In vitro targeting of a cytotoxic analog of luteinizing hormonereleasinghormone AN-207 to ES-2 human ovarian cancer cells asdemonstrated by microsatellite analyses. Anticancer Drugs, 2001,12, 71-78.
75. Nagy, A.; Schally, A. V. Targeting cytotoxic conjugates of somatostatin,luteinizing hormone-releasing hormone and bombesin tocancers expressing their receptors: a smarter chemotherapy. Curr. Pharm. Des., 2005, 11, 1167-1180.
76. Schally, A. V.; Nagy, A. New approaches to treatment of variouscancers based on cytotoxic analogs of LHRH, somatostatin andbombesin. Life Sci., 2003, 72, 2305-2320.
77. Grundker, C.; Volker, P.; Griesinger, F.; Ramaswamy, A.; Nagy, A.; Schally, A. V.; Emons, G. Antitumor effects of the cytotoxicluteinizing hormone-releasing hormone analog AN-152 on humanendometrial and ovarian cancers xenografted into nude mice. Am.J. Obstet. Gynecol., 2002, 187, 528-537.
78. Bajo, A. M.; Schally, A. V.; Halmos, G.; Nagy, A. Targeteddoxorubicin-containing luteinizing hormone-releasing hormoneanalogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers. Clin. Cancer Res., 2003, 9, 3742-3748.
79. Arencibia, J. M.; Schally, A. V.; Krupa, M.; Bajo, A. M.; Nagy, A.; Szepeshazi, K.; Plonowski, A. Targeting of doxorubicin to ES-2human ovarian cancers in nude mice by linking to an analog of luteinizinghormone-releasing hormone improves its effectiveness.Int. J. Oncol., 2001, 19, 571-577.
80. Arencibia, J. M.; Bajo, A. M.; Schally, A. V.; Krupa, M.; Chatzistamou, I.; Nagy, A. Effective treatment of experimental ES-2 humanovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anticancer Drugs, 2002, 13,949-956.
81. Miyazaki, M.; Schally, A. V.; Nagy, A.; Lamharzi, N.; Halmos, G.; Szepeshazi, K.; Armatis, P. Targeted cytotoxic analog of luteinizinghormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. Am. J. Obstet.Gynecol., 1999, 180, 1095-1103.
82. Emons, G.; Sindermann, H.; Engel, J.; Schally, A. V.; Grundker, C. Luteinizing hormone-releasing hormone receptor-targeted chemotherapyusing AN-152. Neuroendocrinology, 2009, 90, 15-18.
83. Nagy, A.; Schally, A. V. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial,and prostate cancers. Biol. Reprod., 2005, 73, 851-859.
84. Krebs, L. J.; Wang, X.; Pudavar, H. E.; Bergey, E. J.; Schally, A.V.; Nagy, A.; Prasad, P. N.; Liebow, C. Regulation of targetedchemotherapy with cytotoxic lutenizing hormone-releasing hormoneanalogue by epidermal growth factor. Cancer Res., 2000, 60,4194-4199.
85. Sundaram, S.; Durairaj, C.; Kadam, R.; Kompella, U. B. Luteinizinghormone-releasing hormone receptor-targeted deslorelindocetaxelconjugate enhances efficacy of docetaxel in prostate cancertherapy. Mol. Cancer Ther., 2009, 8, 1655-1665.
86. Sundaram, S.; Trivedi, R.; Durairaj, C.; Ramesh, R.; Ambati, B. K.; Kompella, U. B. Targeted drug and gene delivery systems for lungcancer therapy. Clin. Cancer Res., 2009, 15, 7299-7308.
87. Khandare, J. J.; Chandna, P.; Wang, Y.; Pozharov, V. P.; Minko, T. Novel polymeric prodrug with multivalent components for cancertherapy. J. Pharmacol. Exp. Ther., 2006, 317, 929-937.
88. Dharap, S. S.; Wang, Y.; Chandna, P.; Khandare, J. J.; Qiu, B.; Gunaseelan, S.; Sinko, P. J.; Stein, S.; Farmanfarmaian, A.; Minko, T. Tumor-specific targeting of an anticancer drug delivery systemby LHRH peptide. Proc. Natl. Acad. Sci. U S A., 2005, 102, 12962-12967.
89. Saad, M.; Garbuzenko, O. B.; Ber, E.; Chandna, P.; Khandare, J. J.; Pozharov, V. P.; Minko, T. Receptor targeted polymers, dendrimers,liposomes: which nanocarrier is the most efficient for tumorspecifictreatment and imaging? J. Control Release, 2008, 130,107-114.
90. Minko, T.; Patil, M. L.; Zhang, M.; Khandare, J. J.; Saad, M.; Chandna, P.; Taratula, O. LHRH-targeted nanoparticles for cancertherapeutics. Methods Mol. Biol., 2010, 624, 281-294.
91. Dharap, S. S.; Qiu, B.; Williams, G. C.; Sinko, P.; Stein, S.; Minko, T. Molecular targeting of drug delivery systems to ovarian cancerby BH3 and LHRH peptides. J. Control Release, 2003, 91, 61-73.
92. Pirollo, K. F.; Chang, E. H. Targeted delivery of small interferingRNA: approaching effective cancer therapies. Cancer Res., 2008,68, 1247-1250.
93. Yu, B.; Zhao, X.; Lee, L. J.; Lee, R. J. Targeted delivery systemsfor oligonucleotide therapeutics. AAPS. J., 2009, 11, 195-203.
94. Ozpolat, B.; Sood, A. K.; Lopez-Berestein, G. Nanomedicine basedapproaches for the delivery of siRNA in cancer. J. Intern. Med.,2010, 267, 44-53.
95. Kim, S. H.; Jeong, J. H.; Lee, S. H.; Kim, S. W.; Park, T. G. LHRHreceptor-mediated delivery of siRNA using polyelectrolyte complexmicelles self-assembled from siRNA-PEG-LHRH conjugateand PEI. Bioconjug. Chem., 2008, 19, 2156-2162.
96. Patil, M. L.; Zhang, M.; Taratula, O.; Garbuzenko, O. B.; He, H.; Minko, T. Internally cationic polyamidoamine PAMAM-OH dendrimersfor siRNA delivery: effect of the degree of quaternizationand cancer targeting. Biomacromolecules, 2009, 10, 258-266.
97. Taratula, O.; Garbuzenko, O. B.; Kirkpatrick, P.; Pandya, I.; Savla, R.; Pozharov, V. P.; He, H.; Minko, T. Surface-engineered targetedPPI dendrimer for efficient intracellular and intratumoral siRNAdelivery. J. Control Release, 2009, 140, 284-293.
98. Rahimipour, S.; Ben-Aroya, N.; Ziv, K.; Chen, A.; Fridkin, M.; Koch, Y. Receptor-mediated targeting of a photosensitizer by itsconjugation to gonadotropin-releasing hormone analogues. J. Med.Chem., 2003, 46, 3965-3974.
99. Yang, W. H.; Wieczorck, M.; Allen, M. C.; Nett, T. M. Cytotoxicactivity of gonadotropin-releasing hormone (GnRH)-pokeweed antiviralprotein conjugates in cell lines expressing GnRH receptors. Endocrinology, 2003, 144, 1456-1463.
100. Gho, Y. S.; Chae, C. B. Luteinizing hormone releasing hormone-RNase A conjugates specifically inhibit the proliferation of LHRHreceptor-positive human prostate and breast tumor cells. Mol. Cells,1999, 9, 31-36.
101. Kakar, S. S.; Jin, H.; Hong, B.; Eaton, J. W.; Kang, K. A. LHRHreceptor targeted therapy for breast cancer. Adv. Exp. Med. Biol.,2008, 614, 285-296.
102. La Marca, A.; Carducci, A. A.; Stabile, G.; Rivasi, F.; Volpe, A. Evidence for cycle-dependent expression of follicle-stimulatinghormone receptor in human endometrium. Gynecol. Endocrinol.,2005, 21, 303-306.
103. Simoni, M.; Gromoll, J.; Nieschlag, E. The follicle-stimulatinghormone receptor: biochemistry, molecular biology, physiology,and pathophysiology. Endocr. Rev., 1997, 18, 739-773.
104. Asatiani, K.; Gromoll, J.; Eckardstein, S. V.; Zitzmann, M.; Nieschlag, E.; Simoni, M. Distribution and function of FSH receptorgenetic variants in normal men. Andrologia., 2002, 34, 172-176.
105. Ascoli, M.; Fanelli, F.; Segaloff, D. L. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endocr. Rev.,2002, 23, 141-174.
106. Morbeck, D. E.; Roche, P. C.; Keutmann, H. T.; McCormick, D. J.A receptor binding site identified in the region 81-95 of the betasubunitof human luteinizing hormone (LH) and chorionic gonadotropin(hCG). Mol. Cell Endocrinol., 1993, 97, 173-181.
107. Grasso, P.; Rozhavskaya-Arena, M.; Jr. Reichert, L. E. Cysteineresidues in a synthetic peptide corresponding to human folliclestimulatinghormone beta-subunit receptor-binding domain 81-95 [hFSH-beta-(81-95)] modulate the in vivo effects of hFSH-beta-(81-95) on the mouse estrous cycle. Regul. Pept., 1999, 81, 67-71.
108. Grasso, P.; Santa-Coloma, T. A.; Boniface, J. J.; Jr. Reichert, L. E.A synthetic peptide corresponding to hFSH-beta-(81-95) has thioredoxin-like activity. Mol. Cell Endocrinol., 1991, 78, 163-170.
109. Ulloa-Aguirre, A.; Timossi, C. Structure-function relationship offollicle-stimulating hormone and its receptor. Hum. Reprod. Update,1998, 4, 260-283.
110. Grasso, P.; Santa-Coloma, T. A.; Jr. Reichert, L. E. Synthetic peptidescorresponding to human follicle-stimulating hormone (hFSH)-beta-(1-15) and hFSH-beta-(51-65) induce uptake of 45Ca++ byliposomes: evidence for calcium-conducting transmembrane channelformation. Endocrinology, 1991, 128, 2745-2751.
111. Zhang, X. Y.; Chen, J.; Zheng, Y. F.; Gao, X. L.; Kang, Y.; Liu, J.C.; Cheng, M. J.; Sun, H.; Xu, C. J. Follicle-stimulating hormonepeptide can facilitate paclitaxel nanoparticles to target ovarian carcinomain vivo. Cancer Res., 2009, 69, 6506-6514.
112. Beck, E. P.; Vincenti, D.; Licht, P.; Berkholz, A.; Jager, W.; Lang, N.; Merkle, E. In vitro activity of human chorionic gonadotropin(hCG)--doxorubicin conjugates against ovarian cancer cells. AnticancerRes., 2000, 20, 3001-3006.
113. Gebauer, G.; Fehm, T.; Beck, E. P.; Berkholz, A.; Licht, P.; Jager, W. Cytotoxic effect of conjugates of doxorubicin and human chorionicgonadotropin (hCG) in breast cancer cells. Breast Cancer Res.Treat., 2003, 77, 125-131.
114. Rivero-Muller, A.; Vuorenoja, S.; Tuominen, M.; Waclawik, A.; Brokken, L. J.; Ziecik, A. J.; Huhtaniemi, I.; Rahman, N. A. Use of hecate-chorionic gonadotropin beta conjugate in therapy of lutenizinghormone receptor expressing gonadal somatic cell tumors. Mol.Cell Endocrinol., 2007, 269, 17-25.
115. Vuorenoja, S.; Rivero-Muller, A.; Ziecik, A. J.; Huhtaniemi, I.; Toppari, J.; Rahman, N. A. Targeted therapy for adrenocortical tumorsin transgenic mice through their LH receptor by Hecatehumanchorionic gonadotropin beta conjugate. Endocr. Relat. Cancer,2008, 15, 635-648.
116. Bodek, G.; Vierre, S.; Rivero-Muller, A.; Huhtaniemi, I.; Ziecik, A.J.; Rahman, N. A. A novel targeted therapy of Leydig and granulosacell tumors through the luteinizing hormone receptor using ahecate-chorionic gonadotropin beta conjugate in transgenic mice. Neoplasia, 2005, 7, 497-508.
117. Bodek, G.; Kowalczyk, A.; Waclawik, A.; Huhtaniemi, I.; Ziecik, A. J. Targeted ablation of prostate carcinoma cells through LH receptorusing Hecate-CGbeta conjugate: functional characteristicand molecular mechanism of cell death pathway. Exp. Biol. Med.(Maywood), 2005, 230, 421-428.
118. Xiangbing, H.; Yankai, Z.; Ming, L.; Yong, L.; Yu, Z.; Huiyong, Z.; Yingying, C.; Jing, H.; Yun, X.; Liang, J.; Rongyue, C.; Jingjing, L. The fusion protein of HSP65 with tandem repeats of betahCGacting as a potent tumor vaccine in suppressing hepatocarcinoma. Int. Immunopharmacol., 2010, 10, 230-238.
119. Dadachova, E. Cancer therapy with alpha-emitters labeled peptides. Semin. Nucl. Med., 2010, 40, 204-208.
120. Pool, S. E.; Krenning, E. P.; Koning, G. A.; van Eijck, C. H.; Teunissen, J. J.; Kam, B.; Valkema, R.; Kwekkeboom, D. J.; de Jong, M. Preclinical and clinical studies of peptide receptor radionuclidetherapy. Semin. Nucl. Med., 2010, 40, 209-218.